| Print
Aldeyra Therapeutics (ALDX)
Common SharesThis share can be held in a Dealing accountISALifetime ISAJISASIPP
Company profile
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
Address
131 Hartwell Avenue
Suite 320
Lexington
MA
USA
02421
Telephone
+1 781 7614904
Forecast key dates
Name | Key Date |
---|---|
Aldeyra Therapeutics Inc First Quarter Earnings Results for 2025 | 2025-05-02T00:00:00 |
Aldeyra Therapeutics Inc Annual Report for 2024 | 2025-03-07T00:00:00 |
Aldeyra Therapeutics Inc Third Quarter Earnings Results for 2024 | 2024-11-01T00:00:00 |
Aldeyra Therapeutics Inc Second Quarter Earnings Results for 2024 | 2024-08-02T00:00:00 |
Aldeyra Therapeutics Inc Annual General Meeting for 2024 | 2024-06-28T08:00:00 |
Aldeyra Therapeutics Inc First Quarter Earnings Results for 2024 | 2024-05-02T00:00:00 |
Previous key dates
Name | Key Date |
---|---|
Aldeyra Therapeutics Inc First Quarter Earnings Results for 2024 | 2024-05-02T00:00:00 |
Aldeyra Therapeutics to Host Research & Development Day | 2024-04-25T09:00:00 |
Aldeyra Reviews Clinical Trial Development Plan for Reproxolap in Dry Eye Disease | 2024-03-28T08:00:00 |
Aldeyra Therapeutics Inc Annual Report for 2023 | 2024-03-07T00:00:00 |
Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference | 2024-02-13T16:30:00 |
Aldeyra Therapeutics Inc Third Quarter Earnings Results for 2023 | 2023-11-03T00:00:00 |
Aldeyra Therapeutics Inc Second Quarter Earnings Results for 2023 | 2023-08-03T00:00:00 |
Aldeyra Therapeutics Inc Annual General Meeting for 2023 | 2023-06-30T08:00:00 |
Aldeyra Therapeutics Inc First Quarter Earnings Results for 2023 | 2023-05-04T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.